Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KJ101

Phase 2Small molecule

SShanghai Bao Pharmaceuticals Co., Ltd.

KJ101 is one of 2 small molecule programs targeting Phase II Clinical Trial. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase II Clinical TrialRecruiting

Phase II Clinical TrialPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Phase II Clinical Trial

#DrugCompanyPhaseTrials

Carbon Nanoparticle-Loaded Iron

SSichuan Enray Pharmaceutical Sciences Company

KJ101

SShanghai Bao Pharmaceuticals Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phase II Clinical Trial1 trial

Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns

Recruiting·SShanghai Bao Pharmaceuticals Co., Ltd.·Phase 2·NCT07025408·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KJ101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KJ101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KJ101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Bao Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Bao Pharmaceuticals Co., Ltd.

Related News